Residual Pulmonary Hypertension in Patients After Mitral Valve Surgery The Impact of Rheumatic Etiology

Diab Mutlak MD, Shemy Carasso MD, Jonathan Lessick MD DSc, Izhak Kehat MD PhD, Doron Aronson MD, Shimon A. Reisner MD, Yoram Agmon MD

> Echocardiography Laboratory and Heart Valves Clinic Rambam Health Care Campus Technion-Israel Institute of Technology, Haifa

IHS 2013 Annual Scientific Meeting, Jerusalem

April 23 2013

DISCLOSURES

None (all co-authors)

Background

- Residual pulmonary hypertension (PHT) not uncommon following successful mitral valve surgery
- Determinants of residual PHT poorly defined
 - Impact of rheumatic etiology on post-operative pulmonary artery systolic pressure (PASP) ?

Methods

- Study population
 - 122 pts s/p mitral valve surgery (replacement n=88; repair n=34)
- Exclusion criteria
 - Overt mitral prosthesis dysfunction / mean $\Delta P > 8$ mmHg
 - Concomitant aortic prosthesis or AS / AR (≥ moderate)
 - LVEF < 50%
 - Measurements of PASP not available (pre- / post-operative)
- The factors associated with elevated post-operative PASP were determined (multivariate linear & logistic regression)

Results

Clinical & Echocardiographic Characteristics

	Comparison by Etiology			Comparison by Post-operative PASP			
	RHD (n = 62)	Non-RHD (n = 60)	Р	≥ 35 mmHg (n = 61)	< 35 mmHg (n = 61)	Р	
Age at last echo, yrs	65±11	64±15	0.8	69±10	60±14	<0.001	
Male, n (%)	12 (19)	41 (68)	<0.001	17 (28)	36 (59)	0.001	
Follow-up post-op, yrs	5.7 (2.4-10.2)	2.7 (1.0-6.6)	0.001	5.0 (1.5-9.7)	3.2 (1.0-6.9)	0.05	
Heart rate, min-1	70±14	69±13	0.8	69±14	70±14	0.52	
Atrial fibrillation, n (%)	31 (50)	13 (22)	0.001	33 (54)	11 (18)	< 0.001	
LA dilatation*, n (%)	38 (61)	15 (25)	<0.001	36 (59)	17 (28)	0.001	
Mitral prosthesis, n (%)	62 (100)	26 (43)	<0.001	50 (82)	38 (62)	0.02	
Mean mitral ΔP , mmHg	4.7±1.7	4.3±1.7	0.2	4.8±1.7	4.1±1.7	0.02	
PASP – pre-op, mmHg	43±16	35± 12	0.01	55±17	46±18	0.007	
PASP – post-op, mmHg	55±19	46±16	0.001	49±14	29±4	<0.001	
RHD, n (%)				39 (64)	23 (38)	0.004	

* Moderate or severe LA dilatation (visual assessment); continuous data – mean ± SD or median (25-75%)

Results

Predictors of Post-op PASP 1

	Linea	r Regress	ion	Logistic regression PASP ≥ 35 mmHg		
Variable	В	95% CI	Р	OR	95% CI	Р
Age at last echo, per 10 yrs	2.9	1.2-4.7	0.001	1.7	1.1-2.6	0.02
Male	- 4.2	(- 8.5)-0	0.05	0.3	0.1-0.7	0.004
Atrial fibrillation	9.1	4.6-13.6	<0.001	5.0	1.9-13.4	0.001
Trans-mitral ΔP (mean) > 4 mmHg*	6.7	2.5-10.8	0.002			
PASP – pre-op, per 10 mmHg	1.8	0.6-3.0	0.004			
PASP – pre-op ≥ 50 mmHg				3.2	1.3-8.0	0.01

* Median value in study population

Independent predictors of PASP \geq 50 mmHg (n=22): age, AF, trans-mitral ΔP

Rheumatic etiology entered (forced) into models:

- Linear model
- Logistic model (PASP ≥ 35 mmHg)
- Logistic model (PASP ≥ 50 mmHg)

<u>P value</u>
0.25
0.6
0.24

Summary

- Residual PH common following *successful* mitral valve surgery
 - 50% post-op PASP \geq 35 mmHg
 - 18% post-op PASP ≥ 50 mmHg
- High frequency of rheumatic etiology in pts with residual PHT
- Independent predictors of post-op PASP 1:
 - Age (@ end of f/u), female gender
 - Atrial fibrillation (@ end of f/u)
 - Pre-operative PHT
 - Elevated trans-mitral ΔP (minor PPM; overt PPM excluded)
- Rheumatic etiology not an independent predictor of post-op PASP 1
 - Association with post-op PHT via its association with other risk factors for post-op PHT (female gender, AF, pre-op PHT)